Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 1

Conditions

Brain Neoplasms 3Neoplasm Metastasis 2Lung Neoplasms 2Cognitive Dysfunction 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Tobacco Use Disorder 1Small Cell Lung Carcinoma 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Neurotoxicity Syndromes 1Melanoma 1Glioblastoma 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Memantine 2acetaminophen, aspirin, caffeine drug combination 1Transcranial Direct Current Stimulation 1Time 1Sugars 1Sirolimus 1Riluzole 1Referral and Consultation 1Ramipril 1Radiotherapy, Intensity-Modulated 1Palliative Care 1Ibuprofen 1Exercise 1Donepezil 1Cognitive Behavioral Therapy 1Cannabidiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Cognitive Dysfunction × Memantine × Clear all
NCT02360215 2025-04-23

Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases

NRG Oncology

Phase 3 Completed
518 enrolled 40 charts
CNS

Brain Neoplasms, Cognitive Dysfunction

NCT04033419 2023-04-20

Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer

UNC Lineberger Comprehensive Cancer Center

Phase 2 Completed
55 enrolled 21 charts

Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡